KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Research & Development (2016 - 2025)

Vertex Pharmaceuticals has reported Research & Development over the past 17 years, most recently at $973.7 million for Q4 2025.

  • Quarterly results put Research & Development at $973.7 million for Q4 2025, down 2.5% from a year ago — trailing twelve months through Dec 2025 was $3.9 billion (up 7.69% YoY), and the annual figure for FY2025 was $3.9 billion, up 7.69%.
  • Research & Development for Q4 2025 was $973.7 million at Vertex Pharmaceuticals, roughly flat from $977.7 million in the prior quarter.
  • Over the last five years, Research & Development for VRTX hit a ceiling of $998.7 million in Q4 2024 and a floor of $448.7 million in Q2 2021.
  • Median Research & Development over the past 5 years was $787.4 million (2023), compared with a mean of $759.1 million.
  • Biggest five-year swings in Research & Development: dropped 5.37% in 2021 and later surged 38.12% in 2022.
  • Vertex Pharmaceuticals' Research & Development stood at $567.8 million in 2021, then rose by 22.24% to $694.1 million in 2022, then grew by 18.8% to $824.6 million in 2023, then increased by 21.11% to $998.7 million in 2024, then decreased by 2.5% to $973.7 million in 2025.
  • The last three reported values for Research & Development were $973.7 million (Q4 2025), $977.7 million (Q3 2025), and $978.4 million (Q2 2025) per Business Quant data.